Edison Investment Research - Aberdeen Standard Equity Income Trust (ASEI) Standard Life Equity Income Trust - Unconstrained approach to UK equity investing

Report

Edison Investment Research

Mel Jenner

Standard Life Equity Income Trust - Unconstrained approach to UK equity investing

Standard Life Equity Income Trust (SLET) has been managed by Thomas Moore since 2011. He aims to generate above-average income and real capital and income growth from a portfolio of UK equities, which is invested across the market cap spectrum. Following an index-agnostic approach, the manager has restructured SLETâ€™s income stream over the past few years and shareholders are now enjoying a higher distribution, with less revenue going into reserves. The board has recently announced a higher than previously forecast final dividend for FY17 and says the annual dividend in FY18 will be at least 5% higher than the FY17 distribution. SLETâ€™s current dividend yield is 3.5%.

17/01/2018 8 EN

Underlying

Aberdeen Standard Equity Income Trust

Standard Life Equity Income Trust is an investment company and carries on business as an investment trust. Co. provides a managed portfolio of U.K. quoted companies. The management of Co.'s investments and the day to day operation of Co. is delegated to Standard Life Investments (Corporate Funds) Limited.

See profile

GB0006039597 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Mel Jenner

Other Reports on these Companies

Hardman & Co

The Hardman & Co Monthly: September 2023

Feature article: Equity Income – UK or Global? Should investors widen their horizons? Introduction: ► The UK Equity Income sector (UKEI) is the fourth-largest investment company (IC) sector in the Association of Investment Companies’ (AIC) universe, with £12.5bn of assets (as at August 2023), and is the traditional home for investors looking for income in the equity market. ► The UKEI not only provides investors with a better dividend yield than the general UK market but also has a strong track record of dividend growth. Indeed, many funds feature on...

September 1, 2023 September 1, 2023 1 EN

Hardman & Co

Hardman & Co Insight: Equity Income – UK or Global? Should investors widen their horizons?

Introduction ► The UK Equity Income sector (UKEI) is the fourth-largest investment company (IC) sector in the Association of Investment Companies’ (AIC) universe, with £12.5bn of assets (as at August 2023), and is the traditional home for investors looking for income in the equity market. ► The UKEI not only provides investors with a better dividend yield than the general UK market, but also has a strong track record of dividend growth. Indeed, many funds feature on the AIC’s “dividend heroes” list for the number of years of consistent growth. ► The UKEI is also marked by the longevity in ...

August 17, 2023 August 17, 2023 1 EN

UOB

Trip.com (9961 HK): 4Q22: Earnings beat; robust 1Q23 guidance on pent-up demand.

TCOM delivered solid 4Q22 results. 4Q22 net revenue grew 7.5% yoy to Rmb5b and was 1.3% above pre-COVID-19 levels, in line with our expectations. Non-GAAP net profit was Rmb498m, ramping up by 61% yoy, translating to net profit margin of 10%, beating our and street estimates. TCOM guided 1Q23 revenue growth of 90-100% yoy or 3% below 4Q19 levels (55% above street estimates), on pent-up travel demand. Maintain BUY with a higher target price of HK$453.00 (US$58.00).

March 8, 2023 March 8, 2023 1 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

1h / 46m 1h / 46m 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

3h / 41m 3h / 41m 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

5h / 7m 5h / 7m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN